Page 7 - Groupa Strep News Today

-- Company Expects to Initiate VAX-31 Phase 1/2 Study in Healthy Adults This Quarter-- -- Topline Safety, Tolerability and Immunogenicity Results from VAX-31 Phase 1/2 Study Expected in the Second...

-- New Agreement to Establish Global Commercial Manufacturing Capacity for Vaxcytes PCV Candidates, VAX-24 and VAX-31, in Adult and Pediatric Pop...

British scientists have started a pioneering trial to find a vaccine for Group A Strep, which can lead to deadly diseases including meningitis, using a new technique

Scarlet fever is known for causing a rash, but as cases of the bacterial illness spike in Britain people are being advised that this is not in fact the first sign to keep an eye out for

SAN CARLOS, Calif., Sept. 19, 2023 -- Vaxcyte, Inc. , a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial...

A man from Woodbridge who died in March may have contracted a dangerous form of Strep A through a burn on his finger, a court heard.

/PRNewswire/ -- RAIsonance today announced the release of its Fall 2023 Workforce Wellness Risk Forecast Report. This specialized forecast delivers...

Streptococcus (strep A) bacteria can transmit from person to person through coughs and sneezes, and symptoms may be evident on a persons skin.

The Liberals' biomanufacturing and life sciences strategy calls for building on these skills and making Canada one of the top sources of vaccine innovation.

-- Advanced Ongoing VAX-24 Phase 2 Infant Study to Second Stage, Dosing First New Participants in July 2023; Topline Data from Primary Immunization Series...